GLP-1s and Addiction: Alcohol, Smoking, and Behavioral Cravings Research

Patients on semaglutide and tirzepatide have been reporting something unexpected: they drink less, smoke less, and feel less pulled toward compulsive behaviors. What began as anecdotal observations in online forums has now entered peer-reviewed literature with a growing body of observational studies, mechanistic research, and early randomized controlled trials. The GLP-1 story on addiction is still being written, but the neuroscience underlying it is compelling — and the myths that have accumulated around it deserve careful examination.

The Neuroscience: GLP-1 Receptors in the Reward System

To understand why GLP-1 medications might affect addictive behaviors, it helps to understand where GLP-1 receptors actually exist in the brain. The dominant narrative has been that GLP-1 agonists reduce hunger by acting in the hypothalamus. But GLP-1 receptors are also expressed in the mesolimbic dopamine system — the brain’s reward circuitry — including the:

• Nucleus accumbens — central to reward anticipation and hedonic processing
• Ventral tegmental area (VTA) — origin of dopaminergic reward signaling
• Prefrontal cortex — executive control over impulsive behavior

Preclinical rodent studies have shown for over a decade that GLP-1 receptor activation reduces self-administration of alcohol, nicotine, cocaine, and opioids. Animals on GLP-1 agonists consume less alcohol when given free access, show reduced reinstatement behavior (the animal model of relapse), and demonstrate decreased cue-induced craving responses. These effects occurred in brain regions anatomically distinct from the hypothalamus, confirming that appetite suppression alone cannot explain the findings.

The translation from rodents to humans is never guaranteed — but the convergence of mechanistic plausibility with human observational data is making this an active frontier of addiction medicine research.

To understand the full scope of GLP-1 effects beyond weight loss, visit the coastal Georgia GLP-1 news hub at Scale Solutions.

Myth #1: The Addiction Effect of GLP-1s Is Just Anecdotal

This was fair to say in 2022. It is no longer accurate.

Several significant observational studies and early RCTs have now been published in peer-reviewed journals:

Alcohol use disorder (AUD):

• A large JAMA Psychiatry 2024 study using Swedish registry data found that semaglutide users with alcohol use disorder had significantly lower rates of alcohol-related hospitalizations and events compared to matched controls taking other diabetes or obesity medications. The effect was statistically robust even after adjusting for multiple confounders.
• A separate real-world data analysis (Veterans Affairs population) found that patients prescribed GLP-1 agonists showed a measurable reduction in alcohol consumption tracking metrics compared to non-users.
• The National Institute on Alcohol Abuse and Alcoholism (NIAAA) has funded multiple randomized controlled trials specifically testing semaglutide and exenatide as potential treatments for alcohol use disorder — an institutional commitment that reflects the strength of the preliminary data.

Nicotine and smoking:

• Pilot studies and observational data suggest GLP-1 users report reduced cigarette cravings and higher cessation rates. A 2024 case series and registry analysis found semaglutide users were more likely to have quit smoking in the prior year compared to matched controls, though this remains correlational.
• Dedicated smoking cessation RCTs using GLP-1 agonists are ongoing, and preliminary results from some pilots suggest meaningful reductions in cigarettes per day and craving scores.

Other substances:

• Observational data from large insurance claims databases (published in 2024) showed reduced rates of opioid overdose events in GLP-1 users compared to matched non-users — a finding that has generated substantial interest in addiction medicine circles.

Myth #2: GLP-1s Should Be Used Off-Label to Treat Addiction Now

While the research is increasingly compelling, it is critical not to leap from “promising preliminary evidence” to “established treatment.” GLP-1 agonists are not FDA-approved for alcohol use disorder, smoking cessation, or any addiction indication as of 2025. The research, though exciting, is at an early stage for these applications.

Several important limitations temper the current evidence:

• Most data is observational. Observational studies can identify associations but cannot prove causation. Selection bias is possible: people who seek GLP-1 therapy may differ in health-seeking behavior from those who don’t.
• Dedicated addiction RCTs are still enrolling or reporting. The NIAAA-funded trials will provide the definitive efficacy and safety data needed to support labeling decisions. Those results are expected 2025–2026.
• Optimal dosing and duration for addiction indications are unknown. The doses studied in weight loss trials may not be the same doses optimal for addiction modulation.
• Addiction treatment requires comprehensive care. Even if GLP-1s prove effective, they are unlikely to work in isolation — behavioral therapy, support groups, and multidisciplinary care remain essential.

Physicians at Scale Solutions approach GLP-1 prescribing with this kind of scientific nuance. To learn about Dr. Donald L. Gates’ approach to evidence-based treatment, visit his profile — he has navigated this evolving landscape since 1999.

Myth #3: The Reduced Cravings Are Just Appetite Suppression

This is a reductionist explanation that the neuroscience does not support.

If GLP-1 agents reduced cravings merely by suppressing appetite and making patients less hungry, we would expect the effect to be limited to food-related cravings. But the clinical observations — and the animal models — show effects on alcohol, nicotine, gambling, and even shopping behaviors. These are not calorie-related rewards. They are dopaminergic reward-seeking behaviors driven by the same mesolimbic circuitry that GLP-1 receptors modulate.

The proposed mechanism is that GLP-1 receptor agonism in the nucleus accumbens and VTA modulates dopamine release and dopamine receptor sensitivity, dampening the “wanting” signal that drives compulsive behavior. This is separate from the “liking” signal — patients on semaglutide often still enjoy activities, food, and social rewards; they simply feel less driven to seek them compulsively.

This distinction is clinically important. Patients sometimes describe it as the “food noise” going quiet — an intrusive preoccupation with food that GLP-1s suppress. The same quieting of intrusive reward-seeking cognition appears to extend to other addictive triggers. This is consistent with GLP-1 receptor activity in prefrontal regions that govern inhibitory control over impulsive urges.

What Does the JAMA Psychiatry 2024 Data Actually Show?

The Swedish registry study published in JAMA Psychiatry in 2024 analyzed over 200,000 patients with substance use disorders in the Swedish national health registry, examining outcomes in those who received GLP-1 agonists versus those who did not. Patients on GLP-1 agents showed:

• Significantly reduced rates of alcohol-related inpatient and emergency care events
• Reduced risk of alcohol-related acute events (alcohol poisoning, alcohol-related accidents)
• The effect was strongest in patients with concurrent obesity or type 2 diabetes — but was present even in normal-weight patients with AUD who were prescribed GLP-1s for glucose management

Importantly, the effect was not replicated for cannabis use disorder in the same analysis, suggesting specificity that points away from a generic “feeling better” explanation toward receptor-specific mechanisms.

Smoking and Nicotine: What the Pilots Show

Nicotine and GLP-1 interaction data is earlier-stage than the alcohol data, but several signals are worth noting:

• Varenicline (Chantix), the current gold-standard smoking cessation drug, also acts on nicotinic acetylcholine receptors in the nucleus accumbens — the same reward hub implicated in GLP-1’s potential effects. The anatomical overlap is suggestive.
• A pilot study in patients with obesity who smoked found that semaglutide significantly reduced cigarettes per day (CPD) and craving scores on validated instruments (Questionnaire on Smoking Urges) compared to placebo over 12 weeks.
• Epidemiological data from large claims databases shows GLP-1 users have higher rates of smoking cessation documentation than matched comparators — though causation remains unproven.

The smoking cessation RCTs currently registered on ClinicalTrials.gov will answer whether this effect is real and large enough to be clinically meaningful as a smoking treatment.

Behavioral Addictions: Gambling, Compulsive Eating, and Beyond

Several case reports and small series have described GLP-1 users spontaneously reporting reduced gambling urges, reduced compulsive shopping, and reduced behavioral compulsions. These observations are consistent with the mesolimbic mechanism — if GLP-1 agonists dampen dopamine-driven wanting, all reward-seeking behaviors that rely on that circuit would plausibly be affected.

This is speculative territory, but it is attracting serious research attention. The National Institute on Drug Abuse (NIDA) has flagged GLP-1 receptor agonists as a priority area for addiction pharmacology research in 2024–2025 funding cycles.

Stay current on the latest developments in GLP-1 science at our medical weight loss program page, where we regularly update on research advances that affect our patients in Savannah, Pooler, and Hinesville.

The Bottom Line: Exciting Science, Responsible Caution

The GLP-1 and addiction story represents one of the most unexpected and potentially significant developments in the pharmacology of both obesity and substance use. The evidence is real, growing, and mechanistically coherent. But it is not yet at the level needed to support prescribing GLP-1 agents as primary addiction treatments. The correct clinical posture is: recognize the potential benefit, note it when relevant for your patients, await definitive RCT data, and never delay evidence-based addiction treatment (behavioral therapy, established medications) in favor of an off-label GLP-1 bet.

Learn More About What GLP-1 Therapy Can Do for You

When it comes to GLP-1 medications, who prescribes and where the medication comes from matters enormously. Get GLP-1 treatment from a physician you trust, working with licensed, state-board-accredited compounding pharmacies and FDA-approved brand-name medications. Dr. Donald L. Gates has practiced bariatric medicine since 1999 and personally oversees every patient at Scale Solutions — only sourcing from licensed, accredited pharmacies. Serving patients in Savannah, Pooler, and Hinesville, GA. Call (912) 352-7546 or book a consultation today.

Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. GLP-1 receptor agonists are not FDA-approved for the treatment of alcohol use disorder, smoking cessation, or any addiction indication. Individuals with substance use disorders should seek comprehensive addiction treatment from qualified specialists. Do not adjust any medication regimen without consulting your physician.

Frequently Asked Questions

Can semaglutide help me stop drinking alcohol?

Research suggests GLP-1 agonists like semaglutide may reduce alcohol cravings and consumption through effects on the brain’s mesolimbic reward system. Observational data published in JAMA Psychiatry in 2024 showed reduced alcohol-related events in GLP-1 users with alcohol use disorder. However, semaglutide is not FDA-approved for this purpose, and dedicated clinical trials are still ongoing. Speak with your physician about evidence-based alcohol use disorder treatments.

Why do GLP-1 medications seem to reduce cravings for things other than food?

GLP-1 receptors are expressed in the brain’s mesolimbic reward circuitry — including the nucleus accumbens and ventral tegmental area — which governs all reward-seeking behavior, not just food intake. When GLP-1 agonists activate these receptors, they appear to dampen dopamine-driven “wanting” signals that drive compulsive behavior toward alcohol, nicotine, and other addictive stimuli. This is a neurobiological effect, not simply appetite suppression.

Is it safe to use a GLP-1 medication to quit smoking?

GLP-1 agonists are not currently approved for smoking cessation, and using them off-label for this purpose is not yet supported by definitive RCT evidence. Established first-line options — varenicline (Chantix), nicotine replacement, and behavioral support — have robust evidence. If you are on a GLP-1 for weight or diabetes and notice reduced cigarette cravings, that is a potentially beneficial secondary effect worth discussing with your doctor.

What clinical trials are studying GLP-1s for addiction?

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is funding multiple randomized controlled trials of semaglutide and exenatide for alcohol use disorder. Additional trials are studying GLP-1 agents for nicotine dependence and opioid use disorder. ClinicalTrials.gov lists ongoing studies. Results from several of these trials are expected in 2025–2026 and will substantially clarify the evidence base.

My GLP-1 medication seems to reduce my urge to drink. Should I tell my doctor?

Yes — absolutely share this with your physician. This observation is consistent with emerging research and may be clinically relevant to your overall care plan. It does not mean you should alter your GLP-1 dosing independently, but your physician may want to track this effect, consider it in treatment planning, and ensure you are receiving appropriate support for any alcohol use concerns.